Expanding Beyond Pediatric Strength, Huluwa Pharmaceutical Group's Lactulose Oral Solution Approved

Recently, the Lactulose Oral Solution independently developed by Huluwa Pharmaceutical Group has officially received a drug registration approval from the National Medical Products Administration (NMPA). Huluwa Pharmaceutical Group, known for its strength in pediatric medications, is advancing its expertise into a new phase characterized by "pediatric excellence + expansion into general therapeutic areas". This new drug will also provide a new treatment option for tens of millions of patients in China.

Tackling Key Challenges: Breaking Technical Barriers to Achieve Stability Improvements

Lactulose, recommended by the World Health Organization as a basic laxative and a first-line treatment for hepatic encephalopathy, presents significant technical challenges in controlling molecular stability and bioavailability. Huluwa Pharmaceutical fully leveraged the technical capabilities of its Academician Workstation and achieved breakthroughs in key formulation parameters such as pH adjustment and high-temperature sterilization processes, bringing the product’s stability to an industry-leading level.

Advantages: Dual Regulation for Gut Health Protection

The product adopts a unique bifidogenic factor formulation, which not only relieves constipation symptoms but also effectively regulates the balance of gut microbiota. Compared with conventional laxatives, it offers clinical advantages of "non-irritation to the intestine and non-dependence", making it particularly suitable for the regulation of intestinal motility in elderly patients with habitual constipation and postoperative patients. In addition, by modulating intestinal pH, the product inhibits the growth of ammonia-producing bacteria and reduces blood ammonia levels, thereby comprehensively alleviating symptoms associated with hepatic encephalopathy.

Outlook: A Hundred-Billion-Yuan Market Presents New Opportunities

Data from Menet show that in the first half of 2025, the market size of digestive system therapeutics in China exceeded RMB 100 billion. Industry experts predict that by 2030, China's clinical drug market for hepatic encephalopathy will approach RMB 40 billion, with an expected compound annual growth rate of 12.5%.

To accelerate market deployment, Huluwa Pharmaceutical Group is set to launch the "Golden Escort" initiative. In the offline market, the Group will launch a "Care for Gut Health" campaign across 100 cities and 10,000 retail outlets. In the online market, it will expand rapidly across platforms such as JD Health and Alibaba Health, establishing a closed-loop service integrating online consultation and home delivery of medicines, so that the new drug can benefit public health at an early stage.

Content source: "Menet"